Lundbeck, Longboard Pharmaceuticals
Lundbeck to Buy Longboard Pharma in $2.6 Billion Deal
Lundbeck A/S agreed to acquire Longboard Pharmaceuticals Inc in a $2.6 billion deal that boosts its drug pipeline for serious brain diseases.The Danish pharmaceutical company is offering shareholders $60 per share in cash for US-based Longboard,
Longboard Pharmaceuticals’ stock soars amid Lundbeck’s $2.6 billion deal to acquire the company
H. Lundbeck plans to acquire Longboard Pharmaceuticals in a $2.6 billion deal, the companies announced Monday.
Lundbeck to buy neurology-focused Longboard Pharmaceuticals in $2.6 billion deal
The Danish pharma company Lundbeck said Monday it would buy Longboard Pharmaceuticals in a deal worth $2.6 billion
Lundbeck to acquire Longboard Pharmaceuticals in $2.6B deal
Danish pharmaceutical company Lundbeck will buy Longboard Pharmaceuticals (LBPH) in a deal valued at $2.6 billion, with the former hoping to build off of its pipeline of epilepsy drug treatment. Market Domination hosts Julie Hyman and Josh Lipton take a closer look at the details of the deal.
Denmark's H. Lundbeck To Buy Longboard Pharmaceuticals For $60/share Cash
Danish pharmaceutical company H. Lundbeck A/S (HLUKY.PK, HLUKF.PK) and Longboard Pharmaceuticals, Inc. (LBPH), announced Monday an
Lundbeck to buy California pharma in $2.6 billion deal
The Danish pharmaceutical company, with its US headquarters in Deerfield, is boosting its drug pipeline for serious brain diseases with this deal.
Denmark's Lundbeck bets on epilepsy drug with $2.6 billion Longboard deal
The companies said Lundbeck will acquire all of Longboard's shares for $60 per share, which represents a premium of 54.2% to the stock's last close of $38.90. Longboard's lead drug candidate, bexicaserin,
Longboard Pharmaceutical Stock Soars 51%. It’s Being Bought for $2.6 Billion.
Pharmaceutical company Lundbeck will acquire Nasdaq-listed Longboard Pharmaceutical in a $2.6 billion deal, the two companies said Monday. Denmark-listed Lundbeck will make a tender offer for all shares outstanding of Longboard common stock,
Longboard Pharmaceuticals Strikes $2.6 Billion Deal to Be Acquired by Lundbeck
Longboard Pharmaceuticals (LBPH) on Monday agreed to be acquired by Danish pharmaceutical company H. Lundbeck in a deal with an equity value of about $2.6 billion. Lundbeck will launch a tender offer to purchase all of Longboard's shares for $60 apiece in cash,
FierceBiotech9h
Lundbeck signs $2.5B check for Longboard, seeing blockbuster potential in epilepsy med
After spying blockbuster potential in Longboard Pharmaceuticals’ epilepsy med, brain disease-focused pharma Lundbeck is ...
BioWorld12m
Lundbeck gains bexicaserin with $2.6B Longboard buyout
H. Lundbeck A/S is to acquire Longboard Pharmaceuticals Inc. in an all-cash deal valuing the epilepsy specialist at $2.6 billion. The agreed price of $60 per share is a 54% premium to the closing ...
Lawyer Monthly1h
Baker McKenzie advise Lundbeck in $2.6B Longboard Pharmaceuticals acquisition
Baker McKenzie advise Lundbeck in $2.6B Longboard Pharmaceuticals acquisition.
devdiscourse1h
Latest Health News: Global Vaccine Approvals and Pharmaceutical Developments
Recent health briefs cover WHO's approval of Bavarian Nordic's mpox vaccine for adolescents, funding pledges for WHO's budget ...
Business Times8h
Lundbeck to buy Longboard Pharma in US$2.6 billion deal
H Lundbeck agreed to acquire Longboard Pharmaceuticals in a US$2.6 billion deal that boosts its drug pipeline for serious ...
Zacks.com on MSN4d
CRL to Aid Lundbeck's Neurological Drug Research With AI-Backed Logica
Charles River Laboratories International, Inc. CRL has entered into an agreement with H. Lundbeck A/S (Lundbeck) — a Denmark-based global pharmaceutical company focused on neurological and psychiatric ...